MENU
+Compare
VYNE
Stock ticker: NASDAQ
AS OF
Aug 22 closing price
Price
$0.33
Change
+$0.01 (+3.12%)
Capitalization
6.6M

VYNE VYNE Therapeutics Forecast, Technical & Fundamental Analysis

VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions... Show more

VYNE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for VYNE with price predictions
Aug 22, 2025

VYNE in downward trend: 10-day moving average broke below 50-day moving average on July 31, 2025

The 10-day moving average for VYNE crossed bearishly below the 50-day moving average on July 31, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on July 30, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on VYNE as a result. In of 69 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

VYNE moved below its 50-day moving average on July 30, 2025 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where VYNE declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for VYNE entered a downward trend on August 08, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 17 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 16 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

The Moving Average Convergence Divergence (MACD) for VYNE just turned positive on August 20, 2025. Looking at past instances where VYNE's MACD turned positive, the stock continued to rise in of 35 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where VYNE advanced for three days, in of 230 cases, the price rose further within the following month. The odds of a continued upward trend are .

VYNE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.170) is normal, around the industry mean (19.343). P/E Ratio (0.708) is within average values for comparable stocks, (54.752). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.643). Dividend Yield (0.000) settles around the average of (0.043) among similar stocks. P/S Ratio (29.940) is also within normal values, averaging (304.274).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. VYNE’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VYNE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
VYNE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a company, which engages in development and commercialization of serlopitant products

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
685 Route 202/206 North
Phone
+1 800 775-7936
Employees
10
Web
https://www.vynetherapeutics.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
UNTY52.223.64
+7.48%
Unity Bancorp
NCSM37.001.99
+5.68%
NCS Multistage Holdings
TRMK40.351.97
+5.12%
Trustmark Corp
PTLE0.170.01
+3.39%
PTL Ltd
DUOL331.87-13.65
-3.95%
Duolingo

VYNE and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, VYNE has been loosely correlated with NEVPF. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if VYNE jumps, then NEVPF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VYNE
1D Price
Change %
VYNE100%
+3.47%
NEVPF - VYNE
52%
Loosely correlated
N/A
SYRE - VYNE
36%
Loosely correlated
+3.58%
ABVX - VYNE
34%
Loosely correlated
+3.83%
EYPT - VYNE
32%
Poorly correlated
+1.98%
CRDF - VYNE
31%
Poorly correlated
+2.65%
More